Loading...
Docoh

Oragenics (OGEN)

Oragenics, Inc. is a biopharmaceutical company, which focuses on the development of novel antibiotics and treatments against infectious disease and oral mucositis. Its technology and pipeline is comprised of antibiotics and genetically engineered bacterial strains. The company was founded by Jeffrey D. Hillman and Robert T. Zahradnik in November 1996 and is headquartered in Tampa, FL.

Company profile

Ticker
OGEN
Exchange
CEO
Alan F. Joslyn
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
Noachis Terra Inc. ...
IRS number
593410522

OGEN stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

8 Aug 22
26 Sep 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 17.87M 17.87M 17.87M 17.87M 17.87M 17.87M
Cash burn (monthly) 1.17M 1.39M 1.35M 1.4M 1.13M 1.34M
Cash used (since last report) 3.38M 4.03M 3.91M 4.05M 3.27M 3.88M
Cash remaining 14.48M 13.83M 13.96M 13.81M 14.6M 13.99M
Runway (months of cash) 12.4 9.9 10.3 9.9 12.9 10.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
29 Jul 22 Dunton Alan W Non-Employee Director Option Common Stock Grant Acquire A No No 0.3562 220,000 78.36K 220,000
29 Jul 22 Telling Fred Non-Employee Director Option Common Stock Grant Acquire A No No 0.3562 220,000 78.36K 220,000
29 Jul 22 Michael O'Keefe Sullivan Employee Stock Option Common Stock Grant Acquire A No No 0.3562 200,000 71.24K 200,000
29 Jul 22 Charles L Pope Non-Employee Director Option Common Stock Grant Acquire A No No 0.3562 220,000 78.36K 220,000
29 Jul 22 Robert C Koski Non-Employee Director Option Common Stock Grant Acquire A No No 0.3562 220,000 78.36K 220,000
10.6% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 29 28 +3.6%
Opened positions 5 1 +400.0%
Closed positions 4 5 -20.0%
Increased positions 6 10 -40.0%
Reduced positions 7 6 +16.7%
13F shares Current Prev Q Change
Total value 6.92B 695.59M +895.2%
Total shares 12.32M 12M +2.7%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Vanguard 5.06M $1.75M 0.0%
Sara-Bay Financial 2.01M $6.92B 0.0%
Intracoastal Capital 1.49M $670K 0.0%
BLK Blackrock 1.33M $462K +1.4%
Geode Capital Management 749.04K $259K +2.4%
STT State Street 495.56K $172K 0.0%
Renaissance Technologies 209.6K $73K +116.5%
NTRS Northern Trust 181.38K $63K 0.0%
FMR 155.82K $54K +0.0%
Bridgeway Capital Management 140K $49K 0.0%
Largest transactions Shares Bought/sold Change
Renaissance Technologies 209.6K +112.8K +116.5%
Millennium Management 128.73K +110.12K +591.6%
Charles Schwab Investment Management 100.78K +100.78K NEW
HighTower Advisors 89.31K +89.31K NEW
Susquehanna International 25.26K -50.3K -66.6%
Two Sigma Securities 0 -30.26K EXIT
LexAurum Advisors 30K +30K NEW
Buckingham Asset Management 0 -27K EXIT
BLK Blackrock 1.33M +18.06K +1.4%
Geode Capital Management 749.04K +17.74K +2.4%

Financial report summary

?
Competition
NovavaxModerna

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: add, age, barrier, breakdown, burden, cavity, children, circulate, constant, construct, Conventional, COVID, CTA, death, diminished, Durability, durable, encouraged, entry, epithelial, exploring, fleeting, Good, handling, hybrid, immunoglobulin, immunological, induce, injectable, key, Kimberly, layer, meaningful, mechanism, memory, mucosa, Murphy, Novavax, older, parallel, path, pilot, poor, President, profile, published, remote, resident, route, screening, seventy, stringent, strong, temperature, transport, urgency, viable
Removed: accelerating, activation, adjuvanted, advanced, agonist, analytical, April, Aragen, begun, Bioscience, broader, broadly, building, channel, Chinese, closely, deliver, diff, EGI, Eleszto, engineering, exclusive, expedite, extended, extensive, facilitate, foreign, found, furlough, Genetika, ILH, infected, inhibited, inserted, insertion, instituted, Intrexon, large, macroeconomic, microeconomic, monitored, monoclonal, native, neutralization, neutralizing, optimize, Oragen, Ovary, permit, plaque, Precigen, preliminary, pretreatment, PRNT, procedure, projected, prolonged, quorum, recently, refrigerated, released, SAS, Sigma, temporary, titer, transgene, underway, unvaccinated, updated, workforce